We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+57.12%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$2.71B
AUM Growth
+$724M
Cap. Flow
-$65.9M
Cap. Flow %
-2.43%
Top 10 Hldgs %
51.5%
Holding
120
New
32
Increased
23
Reduced
35
Closed
25

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$83.9M
2
GMED icon
Globus Medical
GMED
+$54M
3
CELC icon
Celcuity
CELC
+$51.7M
4
PODD icon
Insulet
PODD
+$46.9M
5
ALKS icon
Alkermes
ALKS
+$39.6M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$183M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$92.4M
3
ELV icon
Elevance Health
ELV
+$83.9M
4
CDTX
Cidara Therapeutics
CDTX
+$73.5M
5
UTHR icon
United Therapeutics
UTHR
+$41.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KIDS icon
51
OrthoPediatrics
KIDS
$586M
$9.33M 0.34%
525,447
+397,447
+311% +$6.96M
TERN
52
DELISTED
Terns Pharmaceuticals
TERN
$8.59M 0.32%
212,710
-7,914,390
-97% -$183M
CDTX
53
DELISTED
Cidara Therapeutics
CDTX
$8.57M 0.32%
38,811
-455,000
-92% -$73.5M
INSM icon
54
Insmed
INSM
$28.7B
$8.44M 0.31%
48,500
+45,950
+1,802% +$8.38M
CERS icon
55
Cerus
CERS
$468M
$8.24M 0.3%
+4,000,000
New +$6.93M
ERAS icon
56
Erasca
ERAS
$6.34B
$8.04M 0.3%
2,162,162
– –
AVTX icon
57
Avalo Therapeutics
AVTX
$989M
$8.03M 0.3%
+441,978
New +$7.46M
CCCC icon
58
C4 Therapeutics
CCCC
$402M
$7.27M 0.27%
3,803,942
-3,250,000
-46% -$7.7M
EOLS icon
59
Evolus
EOLS
$488M
$7.12M 0.26%
1,070,000
-380,000
-26% -$2.57M
CGON icon
60
CG Oncology
CGON
$6.6B
$7.06M 0.26%
170,000
-120,000
-41% -$4.97M
ANAB icon
61
AnaptysBio
ANAB
$1.62B
$6.54M 0.24%
135,000
-491,040
-78% -$19.1M
BLTE
62
Belite Bio
BLTE
$6.44B
$6.46M 0.24%
40,354
-169,646
-81% -$20.1M
GPCR icon
63
Structure Therapeutics
GPCR
$3.74B
$6.26M 0.23%
+90,000
New +$3.67M
ABVX
64
Abivax
ABVX
$11.3B
$6.07M 0.22%
+45,000
New +$4.91M
ORKA
65
Oruka Therapeutics
ORKA
$5.94B
$5.76M 0.21%
+190,000
New +$5.29M
MLTX icon
66
MoonLake Immunotherapeutics
MLTX
$1.53B
$5.27M 0.19%
+400,000
New +$4.72M
NEO icon
67
NeoGenomics
NEO
$2B
$5.03M 0.19%
+427,504
New +$4.61M
NTRA icon
68
Natera
NTRA
$38B
$4.58M 0.17%
+20,000
New +$4.17M
CALC icon
69
CalciMedica
CALC
$11.2M
$4.51M 0.17%
683,904
– –
LUNG icon
70
Pulmonx
LUNG
$88M
$4.5M 0.17%
+2,038,323
New +$3.83M
COGT icon
71
Cogent Biosciences
COGT
$7.14B
$4.26M 0.16%
+120,000
New +$3.37M
INDV icon
72
Indivior Pharmaceuticals
INDV
$4.56B
$3.59M 0.13%
100,000
-1,366,000
-93% -$41.7M
URGN icon
73
UroGen Pharma
URGN
$2.22B
$3.51M 0.13%
150,000
-529,000
-78% -$11.5M
TYRA icon
74
Tyra Biosciences
TYRA
$1.61B
$3.29M 0.12%
+125,000
New +$2.3M
KPTI icon
75
Karyopharm Therapeutics
KPTI
$44.2M
$3.24M 0.12%
+440,000
New +$2.69M
1 2
3
4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Soleus Capital Management held 120 positions worth $2.71B, up 36% from $1.99B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Soleus Capital Management's Q4 2025 filing shows 32 new, 23 increased, 35 reduced and 25 closed positions. Its largest new stake was DexCom: 1,297,094 shares worth $86.1M. The largest sale was Terns Pharmaceuticals, an estimated $183M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 94% a quarter earlier.

  • Soleus Capital Management's largest Q4 2025 buy was DexCom: 1,297,094 shares worth $86.1M.
  • Soleus Capital Management added most to Globus Medical in Q4 2025, an estimated $54M increase.
  • Soleus Capital Management's biggest Q4 2025 reduction was Terns Pharmaceuticals, cutting an estimated $183M.
  • Soleus Capital Management fully exited Elevance Health in Q4 2025, selling an estimated $83.9M.
  • Soleus Capital Management's ten largest holdings make up 51% of its $2.71B portfolio in Q4 2025.
  • Soleus Capital Management opened 32 new positions and closed 25 in Q4 2025.
  • Soleus Capital Management's portfolio value rose 36% quarter-over-quarter to $2.71B.

Based on Soleus Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.